BioCentury
ARTICLE | Clinical News

Anagrelide CR: Phase II started

September 22, 2014 7:00 AM UTC

Galena began an open-label, U.S. Phase II trial to evaluate oral GALE-401 twice daily for >=24 weeks in about 20 patients with elevated platelet counts secondary to essential thrombocythemia and other...